Drug Price Trends for HYDROCODONE-ACETAMINOPHEN

Average Pharmacy Cost for HYDROCODONE-ACETAMINOPHEN

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET	70010-0673-01	0.15741	EACH	2025-05-14
HYDROCODONE-ACETAMINOPHEN 10-300 MG TABLET	71930-0044-52	0.27092	EACH	2025-04-23
HYDROCODONE-ACETAMINOPHEN 10-300 MG TABLET	71930-0044-12	0.27092	EACH	2025-04-23
HYDROCODONE-ACETAMINOPHEN 7.5-300 MG TABLET	71930-0043-52	0.21940	EACH	2025-04-23
HYDROCODONE-ACETAMINOPHEN 7.5-300 MG TABLET	71930-0043-12	0.21940	EACH	2025-04-23

Market Analysis and Price Projections for Hydrocodone-Acetaminophen

Market Overview

The global market for acetaminophen-opioid combinations, particularly hydrocodone-acetaminophen, is experiencing significant growth driven by several key factors. Here are some pivotal aspects of the market:

Growing Demand for Pain Management

The increasing prevalence of cancer and other conditions that cause moderate to severe pain is a major driver of the market. Cancer-related pain, in particular, is a significant concern, with therapies such as chemotherapy, radiation therapy, and surgeries contributing to this pain. As a result, the demand for effective pain management solutions like hydrocodone-acetaminophen combinations is on the rise[1].

Market Size and Growth

The global acetaminophen-opioid combination market is projected to grow from USD 3,144.1 million in 2024 to USD 4,522.6 million by 2034, with a compound annual growth rate (CAGR) of 3.7% over the next decade. This growth is largely attributed to the widespread use of these combinations in pain management[1].

Product Segments

Hydrocodone-Acetaminophen Dominance

The hydrocodone-acetaminophen segment holds a substantial market share, with 49.8% of the market value in 2023. This dominance is due to the availability of a large number of products containing this combination and its effectiveness in managing moderate to severe pain[1].

Indications and Usage

Acute vs. Chronic Pain

The acute pain segment accounts for 58.3% of the market share in 2023, driven by the high prevalence of acute pain, increasing incidence of surgeries, and injuries. Acute pain's short-term treatment duration also reduces the risk of opioid addiction, making hydrocodone-acetaminophen a preferred choice[1].

Cancer-Related Pain

Hydrocodone-acetaminophen combinations are highly used in the management of cancer-related pain. With the increasing prevalence of cancer, the demand for these products is expected to rise further. For instance, in 2023, around 25 billion acetaminophen doses, either alone or in combination with prescription opioid medications, were sold in the U.S. annually[1].

Strength and Dosage

Moderate to High Dose Combinations

Moderate to high dose combinations of hydrocodone-acetaminophen dominated the market with a 45.6% share in 2023. These combinations are widely used due to their potent pain relief and are often prescribed for managing severe pain[1].

Distribution Channels

Hospital Pharmacies

Hospital pharmacies hold a significant share of the distribution channel, with 39.9% in 2023. This is because opioids are highly regulated and require proper prescription and medical supervision, which is often provided within healthcare facilities[1].

Regional Analysis

North America

North America is the leading region in the acetaminophen-opioid combination market, with a value share of 43.5% by the end of the forecast period. This is due to the increasing adoption of these combinations and the presence of a large number of manufacturers in the region[1].

Cost and Effectiveness

Out-of-Pocket Costs

The out-of-pocket cost for hydrocodone-acetaminophen in the U.S. has been relatively stable, with an average cost of $7.52 per prescription in 2022. This cost does not include reimbursement from third-party payers and represents the direct payment made by patients[2].

Cost-Effectiveness Analysis

A cost-effectiveness analysis in Colombia compared hydrocodone-acetaminophen with other opioid combinations. The study found that while hydrocodone-acetaminophen is effective, it is more costly compared to acetaminophen-codeine combinations. However, its effectiveness and widespread use justify its higher cost[3].

Price Projections

Current Pricing

The current prices for hydrocodone-acetaminophen vary based on the formulation and quantity. For example, a 30-day supply of hydrocodone-acetaminophen oral liquid can range from $403.95 to $247.15, depending on the dosage and quantity[5].

Future Pricing Trends

Given the growing demand and the stable to slightly increasing trend in out-of-pocket costs, it is likely that the prices for hydrocodone-acetaminophen will remain relatively stable or see a modest increase. However, factors such as regulatory changes, market competition, and advancements in pharmacogenomics could influence future pricing.

Regulatory and Market Dynamics

Advances in Pharmacogenomics

Advances in pharmacogenomics are paving the way for more personalized pain management strategies. This trend may lead to more targeted use of hydrocodone-acetaminophen combinations, where dosages and formulations are tailored to individual patient profiles, potentially enhancing effectiveness and safety[1].

Market Competition

The market is competitive, with key players such as Purdue Pharmaceuticals L.P., Teva Pharmaceutical Industries Ltd., and Johnson & Johnson. Strategies like acquisitions, funding, and collaborations are common among these players to maintain market share and drive innovation[1].

Key Takeaways

• Growing Demand: The increasing prevalence of cancer and other pain-causing conditions drives the demand for hydrocodone-acetaminophen.
• Market Dominance: Hydrocodone-acetaminophen combinations dominate the market due to their effectiveness and widespread use.
• Cost and Effectiveness: While these combinations are more costly, their effectiveness justifies the higher cost.
• Regional Leadership: North America leads in the adoption and sales of these combinations.
• Future Trends: Advances in pharmacogenomics and stable pricing trends are expected to shape the market.

FAQs

1. What is the primary driver of the hydrocodone-acetaminophen market? The primary driver is the increasing prevalence of cancer and other conditions causing moderate to severe pain.

2. Which segment holds the largest market share in the acetaminophen-opioid combination market? The hydrocodone-acetaminophen segment holds the largest market share, with 49.8% in 2023.

3. How does the out-of-pocket cost for hydrocodone-acetaminophen vary? The out-of-pocket cost for hydrocodone-acetaminophen in the U.S. was $7.52 in 2022, not including reimbursement from third-party payers.

4. What is the impact of pharmacogenomics on the hydrocodone-acetaminophen market? Pharmacogenomics is leading to more personalized pain management strategies, potentially enhancing the effectiveness and safety of hydrocodone-acetaminophen combinations.

5. Which region leads in the adoption and sales of hydrocodone-acetaminophen combinations? North America is the leading region, with a value share of 43.5% by the end of the forecast period.

Sources

1. Global Acetaminophen-Opioid Combination Market Growth - GlobeNewswire
2. Acetaminophen/hydrocodone out-of-pocket cost U.S. 2004-2022 - Statista
3. Cost/effectiveness evaluation of three fixed combinations - Elsevier
4. Acetaminophen/hydrocodone prescription number U.S. 2004-2022 - Statista
5. Acetaminophen/hydrocodone Prices, Coupons, Copay Cards - Drugs.com

Last updated: 2024-12-30